"hivウイルス" の関連情報検索結果
Women and HIV: Get the Facts on HIV Testing, Prevention, and Treatment - fda.gov

Women and HIV: Get the Facts on HIV Testing, Prevention, and Treatment fda.gov
London patient remains HIV-free after 2.5 years off treatment - Aidsmap

London patient remains HIV-free after 2.5 years off treatment Aidsmap
A Hidden Defense Inside Llamas Could Be The Secret to Fighting HIV - ScienceAlert

A Hidden Defense Inside Llamas Could Be The Secret to Fighting HIV ScienceAlert
T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection - ...

T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection Nature
WHO HIVResNet HIV drug resistance laboratory operational framework - World Health Organization (WHO)

WHO HIVResNet HIV drug resistance laboratory operational framework World Health Organization (WHO)
Test and treat studies show high rates of HIV diagnosis, viral suppression - Aidsmap

Test and treat studies show high rates of HIV diagnosis, viral suppression Aidsmap
Scientists use gene-edited stem cells to treat HIV — with mixed success - Nature

Scientists use gene-edited stem cells to treat HIV — with mixed success Nature
Some children who start antiretrovirals very early may control HIV after stopping treatment - Aid...

Some children who start antiretrovirals very early may control HIV after stopping treatment Aidsmap
After viral rebound, dolutegravir-based treatment more likely to suppress HIV - Aidsmap

After viral rebound, dolutegravir-based treatment more likely to suppress HIV Aidsmap
Child with HIV maintains viral suppression for three years off treatment - Aidsmap

Child with HIV maintains viral suppression for three years off treatment Aidsmap
Reappearance of HIV in "Mississippi Baby" poses questions for early treatment - Aidsmap

Reappearance of HIV in "Mississippi Baby" poses questions for early treatment Aidsmap
Nearly a third of babies with HIV given ART very soon after birth have no HIV antibodies two year...

Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel? - Aidsmap

Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel? Aidsmap
Two PEP doses spaced a week apart protect monkeys from injected HIV; one dose might work in human...

Two PEP doses spaced a week apart protect monkeys from injected HIV; one dose might work in humans Aidsmap
Could antibodies be used for children with HIV instead of pills? - Aidsmap

Could antibodies be used for children with HIV instead of pills? Aidsmap
Six-country study shows dolutegravir-based treatment is highly effective in children and adolesce...

Six-country study shows dolutegravir-based treatment is highly effective in children and adolescents Aidsmap
São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatme...

São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatment Aidsmap
Yes, the same life expectancy as HIV-negative people, but far fewer years in good health - Aidsmap

Yes, the same life expectancy as HIV-negative people, but far fewer years in good health Aidsmap
Experts shed light on coronavirus response and its implications for people with HIV - Aidsmap

Experts shed light on coronavirus response and its implications for people with HIV Aidsmap
The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance be...

Fostemsavir salvage therapy continues to look good at 96 weeks - Aidsmap

Fostemsavir salvage therapy continues to look good at 96 weeks Aidsmap
The amber light: the World Health Organization’s position when an HIV viral load is “suppressed b...

At-home support after HIV diagnosis in Uganda helps people get on ART and stick with it - Aidsmap

At-home support after HIV diagnosis in Uganda helps people get on ART and stick with it Aidsmap
People with HIV gain weight faster than HIV-negative people - Aidsmap

People with HIV gain weight faster than HIV-negative people Aidsmap
Long-acting capsid inhibitor GS-6207 confirms safety and antiviral activity - Aidsmap

Long-acting capsid inhibitor GS-6207 confirms safety and antiviral activity Aidsmap
“If we don’t include women in trials, we are not protecting women” – dolutegravir in pregnant wom...

Long-acting injectable treatment maintains viral suppression - Aidsmap

Long-acting injectable treatment maintains viral suppression Aidsmap
Intermittent dosing on HIV dual therapy leads to higher rate of treatment failure - Aidsmap

Intermittent dosing on HIV dual therapy leads to higher rate of treatment failure Aidsmap
The length of time Americans with HIV remain infectious is falling, but slowly - Aidsmap

The length of time Americans with HIV remain infectious is falling, but slowly Aidsmap
HIV treatment in the womb helped five South African baby boys to stay undetectable off therapy - ...

HIV treatment in the womb helped five South African baby boys to stay undetectable off therapy Aidsmap
Therapeutic vaccine shows potential for HIV control off treatment in early study - Aidsmap

Therapeutic vaccine shows potential for HIV control off treatment in early study Aidsmap
Home tests aren’t an accurate way for people on HIV treatment to check they still have HIV - Aidsmap

Home tests aren’t an accurate way for people on HIV treatment to check they still have HIV Aidsmap
HIV incidence fell by three-quarters in Australian gay men, with strong association with treatmen...

Four days on, three days off HIV treatment as effective as continuous therapy, French study finds...

Four days on, three days off HIV treatment as effective as continuous therapy, French study finds Aidsmap
Immune modulator clears pre-cancerous anal lesions - Aidsmap

Ibalizumab, active against highly resistant HIV, now approved in US - Aidsmap

Ibalizumab, active against highly resistant HIV, now approved in US Aidsmap
Point-of-care viral load testing improves treatment outcomes and retention in care - Aidsmap

Point-of-care viral load testing improves treatment outcomes and retention in care Aidsmap
Dolutegravir-based HIV treatment is the safest and most effective choice for pregnant women - Aid...

Dolutegravir-based HIV treatment is the safest and most effective choice for pregnant women Aidsmap
Antiretroviral drug levels in hair strongly predict viral suppression - Aidsmap

Antiretroviral drug levels in hair strongly predict viral suppression Aidsmap
Adherence counselling reverses viral rebound on dolutegravir in 95% of cases - Aidsmap

Adherence counselling reverses viral rebound on dolutegravir in 95% of cases Aidsmap
African studies show that lowering viral load in the community reduces HIV incidence, but is not ...

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing ...

Earlier treatment and higher CD4 counts linked to smaller HIV reservoir - Aidsmap

Earlier treatment and higher CD4 counts linked to smaller HIV reservoir Aidsmap
Poor adherence associated with disruptive life events in young people living with HIV - Aidsmap

Poor adherence associated with disruptive life events in young people living with HIV Aidsmap
COVID-19 pandemic has speeded up the implementation of multi-month dispensing - Aidsmap

COVID-19 pandemic has speeded up the implementation of multi-month dispensing Aidsmap
Experimental antibody plus TLR7 agonist maintains viral suppression in monkeys - Aidsmap

Experimental antibody plus TLR7 agonist maintains viral suppression in monkeys Aidsmap
Weight gain on HIV treatment: drug combinations, not single drugs, need to be focus of quest for ...

Point-of-care viral load tests did not improve viral suppression in Kenyan children - Aidsmap

Point-of-care viral load tests did not improve viral suppression in Kenyan children Aidsmap
Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence o...

Opportunistic infections remain common in people taking HIV treatment in Latin America - Aidsmap

Opportunistic infections remain common in people taking HIV treatment in Latin America Aidsmap
Switching to Biktarvy maintains viral suppression in people aged 65 or over - Aidsmap

Switching to Biktarvy maintains viral suppression in people aged 65 or over Aidsmap
Progress on 90-90-90 HIV targets shows stark gap between eastern and western Europe - Aidsmap

Progress on 90-90-90 HIV targets shows stark gap between eastern and western Europe Aidsmap
Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years - A...

Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years Aidsmap
Options for two-drug simplification expand - Aidsmap

Adolescent-centred interventions lead to a 30-percentage-point increase in viral suppression in N...

Fact check: List of US patents is not evidence that viruses are manmade - Reuters

Fact check: List of US patents is not evidence that viruses are manmade Reuters
Lower CD4 count and unsuppressed HIV raise the risk for severe COVID-19 - Aidsmap

Lower CD4 count and unsuppressed HIV raise the risk for severe COVID-19 Aidsmap
Hepatitis C virtually eliminated in people with HIV in the Netherlands - Aidsmap

Hepatitis C virtually eliminated in people with HIV in the Netherlands Aidsmap
Viral suppression in Uganda improved by more viral load tests, done faster - Aidsmap

Viral suppression in Uganda improved by more viral load tests, done faster Aidsmap
ロシア人気ブロガーのHIVドキュメンタリー、再生1300万回突破 | ロイター - Reuters
